Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Caribou Biosciences (CRBU) Long-Term Debt Repayments (2020 - 2021)

Caribou Biosciences (CRBU) reported Long-Term Debt Repayments of $119000.0 for Q1 2021, up 271.88% on a QoQ basis from $32000.0 in Q4 2020.

Caribou Biosciences (CRBU) has 2 years of Long-Term Debt Repayments data on file, last reported at $119000.0 in Q1 2021.

  • Quarterly Long-Term Debt Repayments changed N/A year-over-year to $119000.0 in Q1 2021, while the trailing twelve-month figure through Dec 2021 was $119000.0 (changed N/A YoY) and the FY2021 annual result came in at $119000.0, up 5.31% from the prior year.
  • Long-Term Debt Repayments climbed to $119000.0 in Q1 2021 per CRBU's latest filing, from $32000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $119000.0 in Q1 2021 and bottomed at $31000.0 in Q3 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Caribou Biosciences 232.46 Mn 114.84 Mn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2021 119,000.00
Mar 31, 2021 119,000.00
Dec 31, 2020 32,000.00
Dec 31, 2020 32,000.00
Sep 30, 2020 31,000.00
Sep 30, 2020 31,000.00